In 2008, Stason launched the Brand Division when we acquired exclusive development and commercialization rights to two early phase novel proprietary compounds in the area of oncology. This division within Stason is focused on New Chemical Entities (NCEs) which provide for unmet medical needs. We are dedicated to building our branded product portfolio through internal development, as well as licensing and acquisition. Through our worldwide strategic alliances, these products will be distributed and/or licensed on a worldwide, or territory specific basis.

In 2009, to expand our portfolio of products, Stason entered into an agreement with an overseas pharmaceutical company to represent their proprietary products in North America.  Through this agreement we will select specific products to develop internally, and at the same time, identify partners to co-develop/sub-license the remaining products.

In May 2009, Stason entered into an exclusive license agreement with a US based company to identify Asian partners for an OB/GYN product currently under development in North America.  The NDA is being prepared to be submitted late 2010.